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Allogeneic haematopoietic cell transplantation (HCT) is potentially curative for many patients with haematological disorders and malignancies. However, the identification of suitable human leucocyte antigen (HLA)-matched donors remains a challenge, particularly for patients of minority or mixed race (Gragert et al, 2014; Pidala et al, 2013; Switzer et al, 2013) . As every individual shares one HLA haplotype with each biological parent and with 50% of siblings, a familial haploidentical donor is immediately available in most cases, avoiding the delays associated with unrelated donor identification. Haploidentical HCT has therefore become a mainstream transplant option Castagna et al, 2014; Fuchs, 2015; Handgretinger, 2014; Martelli et al, 2014 Martelli et al, , 2015 McCurdy et al, 2015; Raiola et al, 2014) .
Graft-versus-host disease (GvHD) represents a common complication in T cell-replete haploidentical-BMT (h-BMT), but is significantly reduced by the administration of cyclophosphamide post-transplant (PT-CY) . Graft engineering strategies are also being evaluated with the aim of reducing GvHD, including the depletion of CD3 + or TCR-ab + and CD19 + cells, concurrently enriching for CD34 + cells, TCR-cd + , NK cells and T regulatory cells (Treg) (Di Ianni et al, 2011a,b; Dvorak et al, 2013; Federmann et al, 2012; Locatelli et al, 2013; Martelli et al, 2014) . While some of these approaches appear promising, they are restricted to centres that have graft-engineering capabilities.
T-cell-replete h-BMT with PT-CY has therefore emerged as a leading h-BMT approach as it circumvents the need to manipulate stem cell grafts and can be applied at any BMT research paper centre (Luznik & Fuchs, 2010; Luznik et al, 2012) . PT-CY, especially when implemented following reduced intensity conditioning (RIC), has been associated with relapse rates as high as 55% (Munchel et al, 2011) . This has prompted the consideration of myeloablative conditioning (MAC) regimens to reduce relapse rates, but at the cost of increasing GvHD and non-relapse mortality Ciurea et al, 2015; Solomon et al, 2015) . In this context, we investigated the feasibility of using the bifunctional mechlorethamine derivative bendamustine (BEN), an active alkylator and purine analogue, following h-BMT (Hartmann & Zimmer, 1972; Tageja & Nagi, 2010) . BEN has been used effectively against lymphomas (Corazzelli et al, 2013; Derenzini et al, 2014; Kahl et al, 2010; Rigacci et al, 2012; Robinson et al, 2008) , chronic lymphocytic leukaemia (Bergmann et al, 2005; Quinquenel et al, 2015) and, more recently, as conditioning for allogeneic HCT (Khouri et al, 2014) . This agent has also been applied as pre-treatment for chimeric antigen receptor T-cell therapy of leukaemias, as it induces a sustained lymphodepletion earlier than other agents (Kalos et al, 2011) . However, BEN has not been studied as a post-transplant immunomodulating agent. Based on this information, we evaluated the potential of BEN to serve as an alternative to PT-CY in mitigating GvHD following h-BMT. Our results indicate that post-transplant BEN (PT-BEN) can control GvHD following MAC and RIC h-BMT. More importantly, graft-versus-leukaemia (GvL) effects were significantly stronger in PT-BEN than PT-CY treated mice. These findings uncover a novel application for BEN and may have a major translational impact on the development of more effective clinical h-BMT approaches.
Methods

Mice
Age-matched 5-12 week-old female CAF1/J and NOD-scid IL2Rc null mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA), CB6F1 from Charles Rivers Laboratories (Wilmington, MA, USA) and BALB/c from the National Cancer Institute (Frederick, MD, USA). Mice were housed in specific pathogen-free conditions and cared for according to the guidelines of the University of Arizona Institutional Animal Care and Use Committee (IACUC). (Cooke et al, 1996) .
Haploidentical bone marrow transplantation
Preparation of total T-cells, CD25
À T-cells, and T-celldepleted BM Total T-cells were isolated from na€ ıve CB6F1 spleens by negative selection using mouse Pan T-Cell Isolation Kit II (Miltenyi Biotec, Auburn, CA, USA) with a purity of >97%.
CD25
+ T-cells were depleted from this population using 
A20 leukaemia and imaging
A20, a BALB/c B-cell lymphoblastic leukaemia cell line (American Type Culture Collection, Manassas, VA, USA), is radio-resistant and has been used previously in murine BMT studies (Chen et al, 2006; Zeng et al, 2014 
Statistics
Kaplan-Meier curves were analysed by log-rank test to determine survival percentages and differences between groups (Kaplan & Meier, 1958; Peto & Peto, 1972) . Mann-Whitney tests were used to determine cell count, weight and GvHD score differences between groups. P values <0Á05 were considered statistically significant.
Study approval
All animal studies were approved by the IACUC at The University of Arizona.
Results
A fully haploidentical-BMT model is utilized as an experimental platform for GvHD ). Besides offering the advantage of evaluating rejection and engraftment, transplantation of CB6F1?CAF1/J recipients is associated with significantly more severe GvHD when compared to that of parent?F1 ( Figure S1 ). As T-cells constitute about 2% of murine bone marrow (Sykes, 1990) , recipients receiving only h-BMT did not develop lethal GvHD, irrespective of the intensity of conditioning. Coinjecting 3 9 10 7 h-SC with 10 7 h-BM cells (h-BMT/SC) resulted in GvHD lethality (Fig 1) . An increase in GvHD mortality relative to TBI intensity was evident in h-BMT/SC ) received myeloablative conditioning (MAC) 1000 cGy or reduced intensity conditioning (RIC) 600 cGy total body irradiation (TBI) on day -1 and h-BM ( 10 7 ) with or without h-SC (3 x 10 7 ) from CB6F1 mice (H-2 d/b ) on day 0. Post-transplant cyclophosphamide (PT-CY) 75 mg/kg was given i.p. on days +3 and +4. Pooled data from 4 experiments (MAC; n=16) and 6 experiments (RIC; n=24). Kaplan-Meier survival curves were generated and analysed using the log-rank test. MAC: h-BMT/SC+PT-CY vs h-BMT/SC and h-BMT P<0Á0001. RIC: h-BMT/SC+PT-CY vs h-BMT/SC P<0Á0001 and vs h-BMT P<0Á035. recipients, with mice receiving MAC dying of GvHD at a median time of 7 d versus 21 d for RIC (Fig 1) .
PT-CY significantly prolonged survival with both conditioning regimens. However, >95% of mice eventually died of GvHD following MAC and 25% following RIC (Fig 1) . Given these limitations of PT-CY, especially with MAC, we sought to evaluate novel agents that can be administered post-transplant to better control GvHD morbidity and mortality and focused our studies on PT-BEN.
Donor cell engraftment is maintained with PT-BEN administration
Before evaluating the effects of BEN on GvHD, it was essential to determine the impact of this drug on donor cell engraftment. Chimerism was evaluated following MAC or RIC. Conditioned CAF1/J recipient mice received CB6F1 h-BM with or without h-SC. All mice receiving MAC achieved full donor chimerism following h-BMT. Mice retained this engraftment with the addition of both h-SC and PT-BEN (Fig 2) . Mice receiving RIC followed by h-BMT had mixed chimerism on day +7, with only half of the mice becoming fully chimeric by day +14. The addition of h-SC to the bone marrow infusion augmented donor chimerism to 60-95% by day +7 and 100% by day +14, which remained stable when assessed on day +77. Mice receiving PT-BEN exhibited 80-95% donor chimerism on day +7, increasing to complete donor chimerism in all mice by day +14 (Fig 2) . These results confirm that PT-BEN maintains donor cell engraftment.
PT-BEN is as efficient as PT-CY at mitigating GvHD
Experiments were first undertaken to evaluate the most effective dose and timing of PT-BEN. We found that a single dose of 30 mg/kg on day +3 was most effective at reducing GvHD ( Figure S2 ). Based on our determination of the maximum tolerated doses (MTDs) of BEN and CY in CAF1/J ( Figure S3 ), we chose a comparable CY dose of 150 mg/kg, remaining within the range (66-200 mg/kg) shown by others to effectively mitigate GvHD (Ganguly et al, 2014; Ross et al, 2013) . Our data confirmed that 150 mg/kg PT-CY on day +3 or 75 mg/kg on days +3 and +4 were equally effective at reducing GvHD (data not shown).
To compare the efficacy of PT-BEN to PT-CY, mice received MAC or RIC TBI, followed by h-BMT/SC and PT-BEN or PT-CY. Compared to animals receiving h-BMT/SC alone, survival was significantly improved or prolonged by both PT-BEN (31% MAC and 88% RIC) and PT-CY (0% MAC and 63% RIC) with no significant difference between the treatment groups ( Fig 3A) . This indicates that PT-BEN is endowed with GvHD protective properties equivalent to those of PT-CY in our model. Mice receiving PT-BEN or PT-CY exhibited comparable weight loss and early GvHD scores (Fig 3B,C) . However, signs of clinical GvHD progressively improved in PT-BEN treated mice, leading to GvHD scores significantly lower than those of PT-CY treated mice ( Fig 3C) . As expected, mice from all groups receiving MAC had more prominent weight loss and corresponding increases in GvHD scores when compared to mice receiving RIC Post-BMT bendamustine reduces GvHD and promotes GvL ª 2016 John Wiley & Sons Ltd (Fig 3B,C) . Together, our data demonstrate that, at these doses, PT-BEN is as effective as PT-CY in reducing GvHD morbidity and mortality in both MAC and RIC murine h-BMT settings.
To further investigate GvHD morbidity, animals receiving h-BMT or h-BMT/SC followed by PT-BEN or PT-CY were euthanized on days +21, +35, or +49 for histological evaluation of colonic and hepatic GvHD. As the majority of mice receiving h-BMT/SC die prior to day +21, we were not able to include them as untreated positive controls. Colons from mice receiving h-BMT without h-SC showed little evidence of GvHD early, with some colonic abnormalities at later time points, probably due to the presence of T-cells in the BM inoculum. In contrast, mice receiving h-BMT/SC with PT-BEN or PT-CY demonstrated mild to moderate subacute multifocal to coalescing colitis with moderate crypt hyperplasia, mixed lymphocytic and neutrophilic infiltrates and, in some cases, mucosal ulceration consistent with GvHD. Histological colon GvHD scores (Burich et al, 2001 ) of mice receiving PT-BEN were comparable to those receiving PT-CY (Fig 4A,B) . Similarly, mice receiving h-BMT alone showed no significant pathology in their livers, while those receiving h-BMT/SC with PT-BEN or PT-CY demonstrated similar degrees of mild multifocal chronic active cholangitis indicative of liver GvHD (Fig 4C) .
The protective effects of PT-BEN against GvHD are not dependent on donor CD25
+
T-cells
Additional experiments were performed to assess the role of donor Treg in PT-BEN-mediated protection from GvHD. Recipient mice received T-cell-depleted (TCD) h-BMT on day 0 with 6 9 10 6 purified splenic T-cells (total T) or
The GvHD observed with total T was not severe enough to allow significant survival advantage with PT-BEN (data not shown). When CD25 + T-cells were eliminated from the haploidentical T-cell inoculum, GvHD lethality and morbidity significantly PT-BEN is as efficient as PT-CY at mitigating GvHD in h-BMT. CAF1/J mice received myeloablative conditioning (MAC) or reduced intensity conditioning (RIC) total body irradiation (TBI) on day -1 and h-BM (10 7 ) with h-SC (3 x 10 7 ) from CB6F1 mice on day 0. Post-transplant bendamustine (PT-BEN) 30 mg/kg was given on day +3 and post-transplant cyclophosphamide (PT-CY) 75 mg/kg was given on days +3 and +4. Kaplan-Meier survival curves were generated and analysed using the log-rank test. increased (Fig 5) . Infusion of 6 9 10 6 CD25 À T-cells on day 0 led to the death of all recipients, with most occurring before day +10, substantiating the importance of CD25 + Treg in suppressing GvHD in this h-BMT model. Treatment of mice receiving 6 9 10 6 CD25 À T-cells with PT-BEN significantly improved survival, from 0% to 50%, at +140 d. Moreover, these surviving mice regained their weight and showed minimal signs of GvHD at day +140 (Fig 5) . These data clearly demonstrate that PT-BEN can suppress GvHD in the absence of donor Treg.
PT-BEN is less myelosuppressive than PT-CY
To further explore the potential benefits of PT-BEN over PT-CY, mouse peripheral blood counts were analysed serially post-transplant. PT-BEN was less myelosuppressive than PT-CY with a day +7 average white blood cell (WBC) count of 4Á5 9 10 9 /l compared to 0Á32 9 10 9 /l following MAC (P<0Á001) and 5Á7 9 10 9 /l compared to 0Á48 9 10 9 /l following RIC (P<0Á00001) (Fig 6A) . PT-BEN maintained a higher WBC count than PT-CY up to day +12 and by day +14 counts had similarly recovered in both groups ( Figure S4A ). PT-BEN was relatively more lymphodepleting than myelosuppressive when compared to PT-CY with a myeloid to lymphoid ratio of 14Á6 compared to 0Á48 following MAC and 17Á6 compared to 0Á55 following RIC on day +7 (Fig 6A) . When analysed daily, PT-BEN treated mice had a higher myeloid to lymphoid ratio up to day +13. By day +14, the ratios were comparable ( Figure S4B ). PT-BEN treated mice, in contrast to PT-CY treated mice, never became neutropenic (defined as <100 neutrophils 9 10 9 /l blood) (von Vietinghoff & Ley, 2008; Zuluaga et al, 2006) when analysed from days +4 to 14 ( Figure S4C ). When compared to PT-CY, PT-BEN treated mice exhibited higher haemoglobin, platelet and red blood cell counts up to day +14 following MAC ( Figure S5A ). There was no clear pattern following RIC ( Figure S5B ).
PT-BEN increases MDSC frequency
Flow cytometric analysis was used to further examine peripheral blood cell populations. Treg, phenotypically defined as CD4 + CD25 + FoxP3 + cells, and myeloid-derived suppressor cells (MDSCs), defined as suppressive CD11b + Gr-1 + cells, are two main immune cell populations widely described for their immunosuppressive properties, which play an essential role in the control of GvHD (Colonna et al, 2011; Highfill et al, 2010) . As the lymphoid counts were extremely low on day +7, it was not feasible to perform an analysis of potential differences in the percentage of Treg, T-cells or B-cells between the PT-BEN and PT-CY groups. FoxP3 + cells comprised 0Á1-0Á2% of peripheral blood cells in PT-BEN and PT-CY groups following MAC or RIC on day +14, with a higher absolute number in PT-CY treated mice. On days +35 and +77, there was a two-fold increase in FoxP3 + cells in the peripheral blood of PT-CY relative to PT-BEN treated groups (Fig 6B) . The absolute lymphoid subset numbers between PT-BEN and PT-CY were not significantly or consistently different, (Fig 6C,D) . In contrast, the number of CD11b + Gr-1 hi cells was significantly higher in recipients of PT-BEN when compared to PT-CY on day +7 following MAC and days +7 and +14 following RIC (Fig 6E) . Importantly, Gr-1 hi cells isolated from the blood and spleen of PT-BEN treated mice strongly suppressed T-cell proliferation ( Figure S6 ), confirming their identity as MDSCs.
BEN enhances MDSC suppressive function and impairs T-and B-cell proliferation in vitro
PT-BEN is lymphodepleting, relatively spares the myeloid compartment and significantly increases MDSCs. We therefore further investigated the differential effects of BEN on these subsets in vitro. MDSCs were generated from na€ ıve BM in the presence of increasing concentrations of BEN. After 3 d in culture, >90% of cells were CD11b + Gr-1 + ( Figure S7 ), with no significant differences between groups. MDSCs generated with higher concentrations of BEN were significantly more suppressive than those generated with lower concentrations (Fig 7A) . Importantly, T-cells from na€ ıve mice stimulated by anti-TCR/CD28 antibodies in the presence of BEN concentrations identical to those used in MDSC generation were less proliferative than those cultured in the absence of BEN. Both CD4 + and CD8 + T-cell proliferation were reduced by BEN, with more significant suppression of CD4 + proliferation.
Suppression of proliferation could not be attributed to loss of T-cell viability (Fig 7B) . When B-cells were cultured with the same concentrations, they became even less proliferative with a significant decrease in viability at 100 lmol/l (Fig 7C) .
PT-BEN mitigates GvHD but maintains GvL in the A20 leukaemia model
As BEN significantly suppresses GvHD, it was essential to determine its effects on GvL, specifically assessing whether anti-tumoural activity was maintained with PT-BEN treatment. First, we determined the possible direct effect of BEN on A20 in vivo. This was an important step to discriminate between the possible immunomodulatory effects of BEN and its direct anti-cancer activity. Fig 8A) . Similarly, in NOD-scid IL2R cnull mice with A20 leukaemia, BEN only prolonged survival by 3 d (Fig 8B) . By comparison, CY demonstrated a more potent direct antitumour activity against A20 (CY vs BEN P<0Á002 in BALB/c and P<0Á006 in NOD-scid IL2Rc null ). The total dose of BEN 60 mg/kg given to these mice represents 85% of the MTD, compared to only 34% of the MTD for CY (150 mg/kg). This result confirms that A20 are more sensitive to CY than BEN. Therefore, PT-BEN could not be compared to PT-CY when tumour was given before transplant, as it would be impossible to distinguish the GvL effects from the direct anti-tumour activity. Experiments were undertaken to determine the impact of PT-BEN on the survival of leukaemia-bearing mice undergoing h-BMT. Given that anti-A20 leukaemia effects of BEN are minimal, an increase in survival of leukaemia-bearing mice would be attributable primarily to GvL activity. A20 tumour-bearing mice received RIC and h-BMT or h-BMT/ SC + PT-BEN. PT-BEN significantly increased survival from leukaemia compared to untreated mice (Fig 8C) .
The preservation of significant GvL activity by PT-BEN was confirmed using luciferase-expressing A20 injected i.v. 1 d after chemotherapy (thereby eliminating any possible direct anti-leukaemia activity). All mice receiving h-BMT/SC died of GvHD without evidence of leukaemia. The survival of h-BMT/SC mice treated with PT-BEN was significantly better than that of animals treated with PT-CY. Importantly, the survival of mice receiving h-BMT/SC + PT-CY was not significantly different than that of mice receiving h-BMT (10 7 ) with 6 x 10 6 total T-cells or 6 x 10 6 CD25-depleted T-cells from CB6F1 mice on day 0. Post-transplant bendamustine (PT-BEN) 30 mg/kg was given on day +3. Shown are survival data and mean clinical graft-versus-host disease scores with SEM. Representivative data from 2 experiments, n=6 mice/group. Kaplan-Meier survival curves were generated and analysed using the log-rank test. CD25 À T vs CD25 À T+PT-BEN P<0Á002, total T vs CD25 À T+PT-BEN P=ns, total T vs CD25 À T P<0Á03. + Gr-1 hi . Gating strategy and representative flow from RIC day +14 are shown. Absolute cell number was calculated using the WBC count and differences were analysed using Mann-Whitney test. *=P<0Á05, **=P<0Á01, ***=P<0Á001, ****=P<0Á0001.
Post-BMT bendamustine reduces GvHD and promotes GvL
ª 2016 John Wiley & Sons Ltd alone, which did not develop clinically significant GvHD or GvL (Fig 8D) . Similarly, in another experiment, mice received RIC, TCD-h-BMT or h-BMT/SC with and without PT-BEN or CY on day +3 and A20-Luc cells i.v. on day +4. Mice were imaged serially. PT-BEN treated mice demonstrated no evidence of A20-Luc leukaemia as late as day +70, while those receiving PT-CY showed onset of leukaemia as early as day +22 with all mice dying of leukaemia by day +48. All untreated h-BMT/SC mice died of GvHD by day +45. This is shown in the images and confirmed by quantification of the photons/s (Fig 9A,B) . These results indicate that although PT-CY efficiently reduces mortality related to GvHD, it concomitantly reduces GvL activity in this model, while PT-BEN does not. The effectiveness of PT-BEN at preserving GvL was confirmed in the MAC and RIC models, using two different doses of SC to induce GvHD with different degrees of severity ( Figure S8 ). This highlights the potential therapeutic benefit of BEN over CY in this setting.
Discussion
Recently, the application of haploidentical HCT has significantly expanded. The integration of PT-CY has emerged as the most widely applied h-BMT approach, partly because of its simplicity. However, high relapse rates observed in the setting of RIC have dampened enthusiasm for this strategy, particularly for patients with acute leukaemias (Ciurea et al, 2015) . In an effort to identify an alternative agent that can readily be used to overcome the deleterious impact of GvHD while maintaining GvL, we evaluated PT-BEN. While BEN is noted for potent immunosuppressive and lymphodepleting activities, its ability to prevent or suppress GvHD when given post-transplant has not been published previously in human or murine BMT models. BEN has, however, been incorporated as a conditioning agent prior to matched allogeneic BMT and donor lymphocyte infusion (Khouri et al, 2014; Sala et al, 2014) .
Using clinically relevant fully haploidentical F1?F1 models, we provide the first evidence that PT-BEN represents an efficient and feasible alternative to PT-CY. Mice receiving h-BMT/SC followed by PT-BEN developed sustained donor chimerism. PT-BEN used at a comparable dose, based on determined MTDs in recipient CAF1/J mice, protected against GvHD as effectively as PT-CY. Additionally, we determined that PT-BEN significantly improved the survival of leukaemiabearing mice receiving RIC and h-BMT/SC compared to those receiving h-BMT alone. This anti-leukaemic effect was mediated primarily through GvL, as even a two-fold increase in the dose of BEN demonstrated minimal direct cytotoxic activity against A20 leukaemia in non-transplanted BALB/c and NODscid IL2Rc null mice. Furthermore, when A20-Luc was given after chemotherapy to avoid the inequity of direct cytotoxic effects of BEN and CY, mice receiving PT-BEN demonstrated a significant delay in leukaemia development compared to mice receiving PT-CY, where both GvHD and GvL were significantly suppressed. Taken together, these data demonstrate that PT-BEN effectively controls GvHD and has significant advantages over PT-CY in preserving GvL activity.
Treg play an essential role in the maintenance of immunological self-tolerance (Sakaguchi et al, 2008) . Extensive evidence has shown the balance between effector T-cells and Treg is critical for the control of GvHD (Ermann et al, 2005; Nguyen et al, 2008; Taylor et al, 2004; Zeiser et al, 2008) . Consistent with previous studies in various allogeneic mismatched murine BMT models, our results indicate that in RIC h-BMT, removal of CD25 + T-cells (which include CD4 + CD25 + FoxP3 + Treg) from the T-cell infusion significantly increases GvHD lethality (Zeiser et al, 2006) . It is believed that the predominant effect of PT-CY depletes alloreactive T-cells early post-HCT (Luznik et al, 2002 (Luznik et al, , 2001 . However, the same group recently reported that CD4 + FoxP3 + Treg were essential for GvHD protection by PT-CY in major histocompatibility complex (MHC)-matched and MHC-mismatched models, with T-cell allografts containing both CD4 + and CD8 + cells (Ganguly et al, 2014) . PT-BEN is also an effective lymphodepleting agent, probably partially exerting its effects by eliminating alloreactive T-cells. In our haploidentical model, PT-BEN significantly increased survival even when allografts were depleted of Treg (7-9% of the total T-cell population). As reported in other models (Ganguly et al, 2014) , we observed that PT-CY led to an increase in Tregs at later time points, while PT-BEN did not. The mechanism of action of PT-BEN therefore appears to differ from that of PT-CY. As PT-BEN is more lymphodepleting (including Treg) than myelosuppressive relative to PT-CY, and results in higher numbers of suppressive CD11b + Gr-1 hi cells in the blood, it is conceivable that MDSCs contribute to its mechanism of GvHD suppression. Additionally, the presence of BEN during MDSC generation in vitro increased their suppressive activity. The same concentrations of BEN markedly decreased the proliferation of CD4 + and CD8 + T-cells and Bcells in vitro. These data suggest that BEN improves MDSC function while reducing T-and B-cell function. It is noteworthy that CD4 + T-cells were more affected by BEN than CD8 + T-cells, suggesting the relative sparing of CD8 + T-cells could contribute to GvL activity. In addition, BEN exhibited more pronounced effects on the proliferation of B-cells than T-cells. B-cells play a pivotal role in the development of chronic GvHD (Schultz et al, 1995; Srinivasan et al, 2012; Young et al, 2012) . It is plausible that the pronounced, longlasting depletion of B-cells by BEN may contribute to its effective long-term control of GvHD in our model. The role of PT-BEN on the interplay of these and other immune cells related to GvHD and GvL requires further elucidation. In summary, we have documented that PT-BEN is an effective agent in suppressing GvHD while maintaining GvL in clinically relevant RIC and MAC experimental haploidentical BMT models. With PT-BEN, preservation of GvL was in striking contrast to the abrogation seen with PT-CY. Additionally, BEN is less myelosuppressive than CY and may decrease the duration of severe neutropenia, significantly reducing the risk of infections (Khouri et al, 2014) . BEN used alongside fludarabine and rituximab as conditioning in allotransplantation was well-tolerated and effective (Khouri et al, 2014) . Its safety profile was recently confirmed in a randomized trial of BEN plus rituximab versus R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) with fewer haematological and other toxicities and infections (Becker et al, 2015) . BEN has not been noted to have the significant cardiac and pulmonary toxicity (Becker et al, 2015) or augmentation of TBI-induced lung damage(Sampath et al, ) from CB6F1 mice on day 0. PT-BEN 30 mg/kg as a single dose or divided over 2 d was given starting on day +3. Pooled data from 5 experiments, n=20-34 mice/ group. Kaplan-Meier survival curves were generated and analysed using the log-rank test. h-BMT vs h-BMT/SC+PT-BEN P<0Á002. (D) CAF1/J mice received RIC TBI on day -1 and h-BMT or h-BMT/SC from CB6F1 mice on day 0. PT-BEN (33 mg/kg) or CY (150 mg/kg) was given on day +3 and 1 x 10 5 A20-Luc cells were injected i.v on day +4. h-BMT/SC+PT-BEN vs h-BMT P<0Á0004 and vs h-BMT/SC+PT-CY P<0Á0005, h-BMT/SC+PT-CY vs h-BMT P=ns. Pooled data from 2 experiments, n=8 mice/group. Fig 9. PT-BEN preserves GvL when given post-h-BMT. (A) CAF1/J recipient mice received reduced intensity conditioning on day -1 and T-cell depleted h-BMT or h-BMT/SC from CB6F1 mice on day 0. Post-transplant bendamustine (PT-BEN) or post-transplant cyclophosphamide (PT-CY) was given day +3 and 0Á5 x 10 6 A20-Luc cells on day +4. Mice were injected with luciferin and imaged serially. At times, cages were imaged concurrently, so images are cropped to only show mice from the indicated group. (B) Quantification of (A) is shown in ln(photons/s/mouse). Group average with SEM is shown (left) until any mouse from the group died and analysed using Mann-Whitney tests. Individual mouse values are also shown (right). Images were analysed using AmiView. n=4-5 mice/group. 2005; Shi-Xia et al, 2010) that is often seen following CY conditioning (Ayash et al, 1992; Braverman et al, 1991; Cazin et al, 1986; Malik et al, 1996; Mills & Roberts, 1979) . BEN, however, may be associated with hyperbilirubinaemia, rash and diarrhoea, which may be confused with onset of GvHD, and its safety post-h-BMT remains to be determined in humans (Becker et al, 2015) . Regardless of these potential limitations, PT-BEN deserves further investigation as a potentially effective post-transplant approach following T cell-replete h-BMT. Given that PT-CY on day +3 and 4 is the standard of care in T-replete h-BMT, a proposed phase I trial at our institution will gradually de-escalate PT-CY while escalating BEN to a dose of 100 mg/m 2 , starting with the day +4 dose.
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